期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

舒尼替尼治疗转移性肾癌的进展 被引量：3

原文传递
导出
摘要 转移性肾癌患者的预后极差,既往细胞因子疗法有效率低,且大多不能持久。舒尼替尼（Sunitinib）已被证实治疗晚期肾癌客观反应率（objective response rate,ORR）可达40%[1-2],并被多家肾癌诊疗指南推荐为一线治疗方案。
作者 吴翔 李学松 何志嵩 周利群
机构地区 北京大学第一医院泌尿外科 北京大学泌尿外科研究所国家泌尿男生殖系肿瘤中心
出处 《中华临床医师杂志（电子版）》 CAS 2012年第3期97-100,共4页 Chinese Journal of Clinicians(Electronic Edition)
关键词 转移性肾癌 治疗方案 舒尼替尼 细胞因子疗法 晚期肾癌 诊疗指南 癌患者 有效率
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献49

  • 1Chow LQ, Eckhardt SG. Sunitinib:From rationa! design to clinica! efficacy. J Clin 0ncol,2007,25 : 884-896.
  • 2Motzer RJ, Micbaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol,2006, 24 : 16-24.
  • 3Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006, 295 : 2516- 2524.
  • 4Motzer R J, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007,356 : 115-124.
  • 5Therasse P, Arbuck SG, Elsenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors, european organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst, 2000,92:205-216.
  • 6National Cancer Institute. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. USA : National Institutes Of Health, 2006-08-09. http ://ctep. cancer, gov/protocolDevelopment/electronic _ applications/docs/ ctcae_index, pdf.
  • 7Cohen HT, McGovem FJ. Renal-cell carcinoma. N Engl J Med, 2005,353 : 2477-2490.
  • 8Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage 1V renal carcinoma. Clin Cancer Res, 2004, 10: 6342s- 6346s.
  • 9Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol, 2002,20:289-296.
  • 10Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell, 2000,103:211-225.

共引文献38

同被引文献25

  • 1MOTZER R J, MICHAELSON M D, REDMAN B G, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma [ J ] . J Clin Oncol, 2006, 24(1): 16-24.
  • 2MOTZER R J, MICHAELSON M D, ROSENBERG J, et al. Sunitinib efficacy against advanced renal cell carcinoma [ J ] .J Urol, 2007, 178(5): 1883-1887.
  • 3MOTZER R J, HUTSON T E, TOMCZAK P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [ J ]. N Engl J Med, 2007, 356(2): 115-124.
  • 4OUDARD S, BEUSELINCK B, DECOENE J, et al. Sunitinib for the treatment of metastatic renal cell carcinoma [ J ] . Cancer Treat Rev, 2011, 37(3): 178-184.
  • 5MOTZER R J, HUTSON T E, TOMCZAK P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma [ J ] . J Clin Oncol, 2009, 27: 3584-3590.
  • 6GORE M, SZCZYLIK C, PORTA C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded- access trial [ J ] . Lancet Oncol, 2009, 10: 757-763.
  • 7ZHOU A P. Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience [ J ] . Asia- Pacific J Clin Oncol, 2012, 8: 132-144.
  • 8UEMURA H, SHINOHARA N, YUASA T, et al. A phase Ⅱ study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety [ J ] . Jpn J Clin Oneol, 2010, 40: 194-202.
  • 9Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU 11248, a muhitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in pa- tients with metastatic renal cell cawinoma [ J ]. J Clin Oncol, 2007, 24(1) :16-24.
  • 10Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma[ J ]. J Urol, 2007, 178(5) : 1883-1887.

引证文献3

二级引证文献8

中华临床医师杂志（电子版）
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部